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ABSTRACT 
Background 
The prevalence of obesity has increased globally and reached pandemic levels. Obesity is 
associated with increased risks of complications during conception, pregnancy and delivery 
as well as during the postpartum period. Obesity is most commonly associated with increased 
risk of giving birth to an infant with high birth weight for gestational age. Among other 
complications, obese women have a higher risk of stillbirth. Better models to identify women 
at risk of having infants large for gestational age or stillbirth is needed to be able to take 
preventive action. In addition, increased knowledge about mechanisms behind the association 
between obesity and stillbirth is needed.   
Methods 
Study I and study II were based on the first trimester database, crosslinked to the Swedish 
Medical Birth register. Predictive models for risk of giving birth to an infant large for 
gestational age and risk of stillbirth were constructed, based on maternal characteristics and 
biochemical markers in maternal blood from early pregnancy.   
Study III compared placentas and cord blood erythropoietin concentrations from pregnancies 
of obese and normal weight women, with the aim to investigate signs of chronic fetal 
hypoxia. Study IV compared placental analyses from pregnancies of obese and normal 
weight women with stillborn and live born infants, with the aim to examine placental factors 
potentially mediating the increased risk of stillbirth with increasing BMI.  
Results 
The predictive model for risk of large for gestational age infants, in early pregnancy, in 
parous women with obesity had an AUC for the receiver operating characteristic (ROC) 
curve of 0.81 (95% CI; 0.79 to 0.82), with a sensitivity of 48 % at a fixed specificity of 90%. 
The predictive model for risk of stillbirth had an AUC for the ROC curve of 0.69 (95% CI 
0.64-0.74). The sensitivity was 28 % at a fixed specificity of 90%. 
The adjusted linear regression analysis showed a significant, positive association between 
maternal body mass index (BMI) and cord blood erythropoietin concentration, (β 0.97 CI 
0.27 - 1.68, P-value 0.01). However, no significant difference in placental lesions between 
obese and normal weight women with uneventful pregnancies were found. 
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The effect of obesity on the risk of stillbirth decreased with 38 % when umbilical cord 
abnormalities were included in the logistic regression model. The effect of obesity on the risk 
of stillbirth decreased with 15% when chorioamnionitis was included in the logistic 
regression model.  
Conclusion 
Predictive models for risk of large for gestational age infants in obese parous women were 
fairly good. Predictive models for risk of stillbirth in overweight and obese women were 
reasonable. However, the capacity of the predictive model increased if small for gestational 
age was included in the model, indicating a potential to improve the predictive capacity if 
estimated fetal weight could be included.  
There are signs of an increased risk of chronic fetal hypoxia in pregnancies of obese women.  
In term pregnancies, umbilical cord abnormalities could possibly explain approximately one 
third of the increased risk of stillbirth with increasing BMI. Chorioamnionitis could possibly 
explain approximately 15% of the increased risk of stillbirth with increasing BMI in term 
pregnancies.   
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1 INTRODUCTION 
 
The proportion of women with overweight or obesity in early pregnancy is continuously 
increasing in the world, including Sweden. The problem with obesity has reached pandemic 
proportions 1, 2. Increasing body mass index (BMI) is associated with increased risks of 
complications during fertilization, implantation, pregnancy, delivery and the post-partum 
period. The risks are increased for both mother and child in the short-term as well as in the 
long-term perspective 3-7.  
One of the most common complications in pregnancies of obese women is giving birth to a 
large for gestational age (LGA) infant. LGA is defined as birthweight equal to or above the 
97th percentile for gestational age and sex (>2 SD) 8. Giving birth to an LGA infant is 
associated with increased risks for both mother and infant during delivery. There are 
increased risks of obesity, high blood pressure and diabetes in adolescence and adulthood for 
the LGA born infant 9, 10. The knowledge of how to identify women at highest risk of giving 
birth to an LGA infant is a prerequisite for the preventive strategies aiming at reducing the 
incidence of LGA infants.  
One of the most severe complications associated with obesity is stillbirth. The risk of 
stillbirth among obese women increase almost linearly with increasing maternal BMI in early 
pregnancy 3. The rates of stillbirth have been stable during the past decades in high-resource 
European countries, while the incidence of neonatal death has continued to decrease. 
Consequently, stillbirth is the main contributor to perinatal death 11, 12. The incidence of 
stillbirth differs between high-resource countries. There are interregional differences in 
incidence within Sweden indicating a possibility to decrease the incidence in some regions. In 
2016 Flenady et al. wrote that “Future research must focus on stillbirth prediction, 
understanding placental pathways to stillbirth and causal pathways to unexplained stillbirth” 
13. In order to further decrease risks of stillbirth, increased knowledge on pathogenic 
mechanisms is needed. Also, early identification of women with high risk of stillbirth may 
open possibilities for prevention. 
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2 BACKGROUND  
2.1 OBESITY 
2.1.1 Definitions 
BMI is defined as an individual’s weight in kilograms divided by the square of the height in 
meters (kg/m2). BMI is strongly correlated with, and therefore often used as a marker of, the 
amount of body fat 14. Overweight and obesity are defined as BMI of 25.0 to 29.9 and BMI ≥ 
30.0 respectively. Obesity is further sub-classified into obesity class I, class II and class III, 
please see table 1. 
Table 1. Classification of BMI by the World Health Organization (WHO) 
BMI (kg/m2) Classification 
>18.5 Underweight 
18.5-24.9 Normal weight 
25-29.9 Overweight 
30-34.9 Obesity class I 
35-39.9 Obesity class II 
≥ 40 Obesity class III 
2.1.2 Prevalence 
The prevalence of obesity is increasing worldwide 2. The most rapid increase has been 
observed in high-income, English-speaking countries 2. In the United States the prevalence of 
obesity among women in reproductive age increased from 28% in 1999 to 34% in 2008 15. 
Most countries in Europe have a prevalence of overweight or obesity between 30-37% in 
women in reproductive age 16. The highest prevalence of overweight or obesity in Europe, 
48.4%, was reported in Scotland 16. In Sweden more than one in three women in early 
pregnancy are overweight or obese compared to one in four 20 years ago, figure 1 12. 
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Figure 1. The increasing proportion of overweight and obesity in early pregnancy in Sweden 
between 1992 to 2016 17.  
2.1.3 Characteristics of overweight and obese women 
The prevalence of overweight and obesity is not equally distributed in society. There is an 
association between pre-pregnancy obesity and country of birth. Women born in Africa, 
Middle East and South America have an increased risk of overweight or obesity compared to 
women born in Sweden. However, women born in Europe (except the Nordic countries), 
North America, Australia, former USSR and Asia have lower risk of overweight or obesity as 
compared to women born in Sweden 18. Besides country of birth, socioeconomic factors are 
important risk factors for obesity, with level of education being one of the most important.  
Women with lower level of education have an increased risk of obesity 18. In addition, 
women with lower level of education had a more prominent increase in BMI between 
pregnancies than higher educated women, with the largest difference observed in women 
with excessive gestational weight gain during the first pregnancy 19. Since women tend to 
gain weight between pregnancies, women with obesity are more often parous women 20.   
2.1.4 Gestational weight gain  
There are risks associated with both higher and lower gestational weight gain than 
recommended during pregnancy 21, table 2   
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Table 2. Institute of Medicine (IOM) 22 recommendations for gestational weight gain  
Pre-pregnancy BMI (kg/m2) Recommended gestational 
weight gain 
>18.5 12.5-18 kg 
18.5-24.9 11.5-16 kg 
25-29.9 7-11.5 kg 
>30 5-9 kg 
 
Women with lower gestational weight gain than recommended have a reduced risk of giving 
birth to a large for gestational age (LGA) infant and an increased risk of giving birth to a 
small for gestational age (SGA) infant, with the highest risk in women with BMI < 18.5 
before pregnancy 21. In addition, lower gestational weight gain than recommended is 
associated with an increased risk of preterm birth 21.  
Women with excessive gestational weight gain have a decreased risk of giving birth to an 
SGA infant and an increased risk of giving birth to an LGA infant. In addition, there is an 
increased risk of cesarean section, gestational hypertension, gestational diabetes (GDM), 
preeclampsia, induction of labor and blood transfusion 21, 23. Obese women with weight loss 
during pregnancy or lower gestational weight gain than recommended have an increased risk 
of preterm birth and an increased risk to give birth to an SGA infant 21. However, weight loss 
between pregnancies in overweight or obese women decreases the risk of giving birth to an 
LGA infant and is not associated with increased risk of preterm birth or SGA 24, 25.  
2.1.5 Obesity and pregnancy complications 
Obesity is a major risk factor for several complications during pregnancy, delivery and 
puerperium 7. Obesity is the most important modifiable risk factor for pregnancy 
complications, including stillbirth, large for gestational age infants, preeclampsia and 
gestational diabetes 3, 26. It has been estimated that, if 10% of women with pre-pregnancy 
obesity achieved a normal weight before pregnancy, 700 fetal deaths per year could be 
prevented in the USA 27.  
2.1.5.1 Obesity and gestational diabetes 
Obesity increases the risk of GDM 28, which is an independent risk factor for preeclampsia 
and LGA 29, 30. 
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Normal pregnancy includes a more insulin resistant state which in some cases reaches a level 
defined as GDM. However, the HAPO study 31, which was an international multicenter study, 
including over 25,000 women without pre-gestational diabetes or GDM, has shown increased 
risks of adverse maternal and neonatal outcomes even at levels of hyperglycemia beneath the 
diagnostic threshold for GDM 29, 31, 32. These findings have led to stricter criteria for the 
diagnosis of GDM. No international or national consensus on screening and diagnosis of 
GDM existed before 2016. However, in 2016 new, stricter criteria for the diagnosis of GDM 
were adopted by the American Diabetes Association and WHO. Since 2018, The Swedish 
National Board of Health recommend the same criteria 33. According to the new criteria, a 
diagnosis of GDM should be given in case of a fasting glucose level ≥ 5.1 mmol/L, and/or a 
glucose level ≥ 10.0 mmol/L at 1 hour after oral glucose tolerance test (OGTT, 75 g glucose) 
and/or a glucose level ≥ 8.5 mmol/L at 2 hours after OGTT 33.   
Risks associated with obesity and risks associated with GDM are partly the same. The risks 
of preeclampsia and hypertension seem to be higher in obese women than in women with 
GDM alone 34. The risk of giving birth to an LGA infant is increased both in women with 
obesity and in women with GDM, with the highest risk in pregnancies with both GDM and 
obesity 29, 30. The impact of obesity and maternal hyperglycemia seems to be independent and 
additive with respect to the risk of giving birth to an LGA infant and to the risk of 
hypertensive disorders in pregnancy, including preeclampsia 29, 34. The stricter criteria for the 
diagnosis of GDM will lead to an increasing number of women being diagnosed. These 
women will be treated with the aim of keeping the levels of glucose in the blood as close to 
normal as possible, to reduce the risks associated with GDM. The benefits of employing 
stricter criteria remain to be investigated.  
2.1.5.2 Obesity and hypertensive disorders 
Essential hypertension is defined as blood pressure ≥ 140/90 mmHg, measured on two 
separate occasions. Pregnancy induced hypertension is defined as blood pressure ≥ 140/90 
after the 20th gestational week, measured on two occasions, in a woman who was 
normotensive prior to pregnancy. Preeclampsia is defined as pregnancy induced hypertension 
with significant proteinuria and/or additional symptoms from other organs, increased creatine 
level, twice normal level of liver transaminases, pulmonary edema or cerebral/visceral 
symptoms 35. 
There are numerous studies reporting increased risk of preeclampsia with increasing maternal 
BMI 4, 36-38. The risks of both mild and severe preeclampsia increase with increasing BMI, as 
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well as the risk of pregnancy induced hypertension 38, 39. The pathophysiology of 
preeclampsia is not fully understood. However, dysfunctional trophoblast invasion and 
migration in the endometrial lining of the uterus resulting in a disrupted remodeling of the 
spiral arterioles, hence reducing placental perfusion, will likely contribute 37.  
Obesity is accompanied by a state of subclinical inflammation, with increased levels of pro-
inflammatory cytokines 40. The inflammatory state of obese women is likely to contribute to 
the increased risk of preeclampsia. The state of vascular inflammation is associated with both 
BMI and hypertension 40.   
It has been shown that hyperinsulinemia is associated with a reduced trophoblast invasion and 
poor placentation 41-43. In addition, hyperinsulinemia inhibits the physiological decrease in 
blood pressure during mid-gestation and increases the risk of hypertension later in pregnancy 
42. Nitric oxide is crucial for keeping normotension during pregnancy 44 and hyperinsulinemia 
leads to decreased nitric oxide production 44. Additionally, the higher levels of pro-
inflammatory cytokines will also contribute to decreased levels of nitric oxide and increased 
levels of vasoconstrictors in maternal blood 37. These mechanisms are likely to contribute to 
the increased risk of hypertension in pregnancies complicated by obesity.   
There is also evidence of a maternal cardiovascular component in the etiology of 
preeclampsia 45. During normal pregnancy, the heart is remodeled with increased chamber 
dimensions, wall thickness and increased mass 45. Pregnancy is a cardiovascular burden with 
increasing blood volume, increasing heart minute volume and a slight increase in heart rate. 
Obese women have less margins than normal weight women to handle the extra 
cardiovascular burden associated with pregnancy 45.    
2.1.5.3 Obesity, time to delivery and mode of delivery 
Duration of first stage of labor increases with increasing maternal BMI as well as if the fetus 
is large 46, 47. Particularly the early phase of the first stage of labor is prolonged in obese 
women 48. However, the second stage of labor is not prolonged in obese women 47. Obese 
women have an increased risk of post term pregnancy 49, resulting in an increased risk of 
induction of labor. It has been shown that obese women needed more doses of misoprostol 
during induction of labor and a longer duration of oxytocin administration at increased 
concentration and they still ran an increased risk of cesarean section 50. Several reviews show 
that obese women have an increased risk of instrumental vaginal birth as well as cesarean 
section 51, 52. It has been hypothesized that the increased risk of cesarean section and a 
prolonged first stage of labor are due to factors like cholesterol incorporated in the 
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myometrium affecting contractility, increase of pelvic soft tissue narrowing the birth canal, 
increased frequency of macrosomic fetuses and a poorer response to oxytocin 53. However, 
there is evidence that obese women have the same strength of contractions as normal weight 
women 54.  
2.1.6 Minimizing risks associated with obesity during pregnancy- what 
can be done? 
Obesity is associated with risks of adverse outcome for both mother and child. Intervention 
programs including diet and exercise during pregnancy have demonstrated a slight reduction 
in gestational weight gain, however, not reduced BMI and have failed to show decreased 
risks except for small differences in birthweight and a small decrease in the incidence of 
GDM 55. After bariatric surgery the risk of GDM, LGA, hypertension and post-partum 
hemorrhage decreases; however, the risk of SGA increases 56. Weight-loss between 
pregnancies leads to decreased risks of GDM and LGA without increased risks of SGA or 
preterm birth 24. Observational studies that have reported decreased risks of GDM, LGA and 
hypertension with weight loss between pregnancies have compared women who really did 
lose weight with women who did not. Supposing BMI is the harmful exposure, decreased 
risks cannot be expected if the exposure is not changed. In interventional studies during 
pregnancy most women will not lose weight. Hence, the different results may be explained by 
different degree of exposure.    
Breastfeeding is less frequent and of shorter duration in obese women than normal weight 
women 53. However, the effect of breastfeeding on post-pregnancy weight loss is conflicting 
57, 58.  
In conclusion, actions taken during pregnancy have failed to substantially affect the risks of 
LGA, birthweight, GDM and hypertension. The most effective action is to achieve a BMI as 
close to normal as possible before pregnancy 24. Dietary advice with limited gestational 
weight gain, awareness of increasing blood pressure, estimated fetal weight and knowledge 
about a normal labor in obese women, may help reduce the negative effects of obesity during 
pregnancy. Women with overweight or obesity have a higher frequency of substantial inter-
pregnancy weight gain 59, which will further increase their risks due to obesity. A low 
gestational weight gain during pregnancy is associated with a decreased risk of inter-
pregnancy weight gain 58, 60.  
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2.2 STILLBIRTH 
In Sweden, stillbirth is defined as a fetus born dead at gestational week ≥ 22+0 61. The 
incidence of stillbirth is highest in low-resource regions of the world but remains a problem 
in high-resource regions where stillbirth accounts for the majority of all perinatal deaths. The  
average stillbirth rate is around 5/1000 births in high-income regions and in Sweden 3-4/1000 
births 62, 63. During the past decades the incidence of stillbirth has declined slowly or remain 
stable over time in most high resource countries 12, 63, 64. However, during the same time 
period the incidence of neonatal mortality has declined faster and consequently the proportion 
of perinatal deaths due to stillbirth has increased, figure 2 11, 12.  
 
Figure 2. The proportion of stillbirth and neonatal death (day 0-6) for each year per 1000 
born infants in Sweden 65. 
Several risk factors for stillbirth have been identified, including, low and high maternal age, 
nulliparity, previous stillbirth and maternal medical conditions such as diabetes, 
preeclampsia, systemic lupus erythematous (SLE) and antiphospholipid syndrome 26, 66. The 
two main modifiable risk factors are obesity and smoking 26. Several of the risk factors are 
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associated with placental dysfunction and fetal growth restriction, which is found in a large 
proportion of stillbirths 26, 62, 64, 67. In addition, fetal anomalies, infections, umbilical cord 
complications and placental abruption might cause stillbirth. However, for a large 
proportion of stillbirths the cause is unknown 64, 68.  
Causes of stillbirth differ between preterm and term pregnancies. Infections and umbilical 
cord complications are more common in term stillbirths, whereas preeclampsia and 
abruptio placental are more common in pre-term stillbirths 69. Fetuses small for gestational 
age have an increased risk of stillbirth both in term and pre-term pregnancies. However, the 
proportion of SGA fetuses in term stillbirths is much lower than the proportion of SGA 
among pre-term stillbirths 69.  
2.2.1 Obesity and the risk of stillbirth 
The risk of stillbirth increases with increasing maternal BMI 3. Obese women have an 
increased risk of hypertension, preeclampsia and impaired placental function 67, which are 
possible contributing factors to the association between obesity and stillbirth 70. However, the 
risk of stillbirth remains increased in obese women also after taking obesity-related 
conditions and obesity associated factors into account, such as preeclampsia, diabetes, 
hypertension, ethnicity, maternal age, parity, smoking and socioeconomic status 5, 26, 71, 72. 
These findings indicate that obesity per se has an independent impact on the risk of stillbirth 
70. There are probably several mechanisms contributing to this effect; placental dysfunction 
and inflammation as well as metabolic and hormonal changes associated with obesity have 
been suggested 70.  
Fetuses of obese women have an increased risk of hyperinsulinemia, measured as level of C-
peptid in cord blood 32, 73. Fetal hyperinsulinemia may lead to chronic fetal hypoxia 74. 
Experimental studies on fetal rhesus monkeys and lambs demonstrate that induced 
hyperinsulinemia increases risk of hypoxia 75. Hyperglycemia during pregnancy in women 
with type 1 diabetes mellitus increases the risk of stillbirth 76.  
In addition to other functions, fat tissue plays a role in the immune system, which enhances 
the inflammatory state in obese women via increased number of macrophages and increased 
adipokines 77. The low-grade inflammation is supposed to partly explain the increased risks 
of cardiovascular disease among obese persons as well as increased risk of cancer associated 
with obesity in non-pregnant individuals 77. During pregnancy the low-grade inflammation is 
thought to contribute to some of the pregnancy complications associated with obesity such as 
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preeclampsia, gestational diabetes and hypertension 40. Chorioamnionitis has been suggested 
to account for approximately 10% of the increased risk of stillbirth due to obesity 78.  
It has been shown that both SGA and LGA fetuses have an increased risk of stillbirth, 
however, in particular SGA fetuses 79. Obese women have a reduced risk of giving birth to an 
SGA infant 80, 81. However, SGA fetuses with obese mothers are at higher risk of stillbirth 
compared to SGA fetuses with normal weight mothers 82. Both SGA and LGA fetuses are at 
increased risk of chronic fetal hypoxia 80. SGA fetuses have a higher incidence of low oxygen 
levels in both the umbilical vein and umbilical artery 80. The umbilical vein transports 
oxygenated blood from the woman to the fetus and the umbilical artery contains de-
oxygenated blood from the fetus to the woman. SGA fetuses may have decreased levels of 
oxygen due to impaired placental function, possibly also influencing fetal growth 80. LGA 
fetuses have a higher prevalence of low oxygen levels in the umbilical artery, which may 
reflect an increased oxygen demand 80.   
2.2.2 Reducing the number of stillbirths – what can be done? 
To be able to further decrease the incidence of stillbirth, more knowledge about the causes 
of stillbirth is needed. One way to collect more structured information is to use audit 
protocols to collect detailed characteristics of the stillbirths, such as the fetal and maternal 
associated conditions, the placenta pathology and the autopsy 64. A project with this aim has 
been going on in Stockholm since 1998 by the Stockholm stillbirth group. Audit protocols 
can also be used to try to find avoidable cases and possible preventive strategies.  
A large proportion of stillborn infants are born SGA 83.  It has been advocated that repeated 
estimations of fetal weight would detect fetuses at risk to allow interventions that could 
potentially decrease stillbirth rates 84. A screening ultrasound in gestational week 35-36 
would potentially identify a larger proportion of SGA fetuses; however, the predictive 
capacity for negative perinatal outcome among the found SGA fetuses is poor 85, 86. In 
addition, an ultrasound in gestational week 35-36 will miss most of SGA stillborn fetuses 
since the SGA fetuses who will suffer from stillbirth, to a large extent, die in earlier 
gestational weeks 69. The incidence of SGA among stillborn infants in the Stockholm 
Stillbirth database is around 10% for term infants and around 40% for pre-term infants, 
figure 3 8. Hence, a third trimester ultrasound in a low-risk population has been shown to be 
able to detect a larger proportion of SGA fetuses, although not affect the outcome for the 
infant 87-89. However, ultrasound examinations aiming to find SGA fetuses may be 
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beneficial for certain groups of high-risk women. Predictive models can possibly be used to 
be able to identify groups where increased surveillance in pregnancy is most needed 13.  
 
Figure 3: Proportion of stillborn term infants SGA no/yes and stillborn preterm infants 
SGA no/yes.   
 
Low-dose aspirin has been widely evaluated as a method for prevention of placental-related 
complications and in particular prevention of pre-eclampsia. It has also been shown to 
decrease the risk of stillbirth with fourteen percent in women with risk factors for stillbirth 
90.  
Sleeping position and sleep disordered breathing could be associated with the risk of 
stillbirth. There are evidence that a supine sleeping position could potentially increase the 
risk of stillbirth 91. The evidence of sleeping disordered breathing as a risk factor for 
stillbirth is conflicting, possibly due to the rare outcome and difficulties to reach enough 
power in studies 92.   
It is known that the risk of stillbirth at term increases for each extra gestational week 93. 
There is an on-going debate about the optimal time for induction of labor due to prolonged 
pregnancy, with the risk of stillbirth and negative neonatal outcome weighted against the 
risk of other adverse effects associated with induction of labor 94. The risk of stillbirth in 
obese women has a more pronounced increase from gestational week 39, compared to 
normal weight women 95. Indicating that induction of labor would have a greater effect in 
preventing stillbirth among obese women compared to normal weight women.  
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In areas where the stillbirth incidence has decreased rates have decreased over the whole 
continuum of gestational ages. This is likely a reflection of an overall improvement in 
perinatal care 96.  
2.2.3 Erythropoietin 
Erythropoietin is a glycoprotein hormone, stimulating red blood cell production 97. 
Erythropoietin is mainly produced in the fetal liver in late pregnancy, and in the infants 
kidneys after birth 98. The fetus has several mechanisms to decrease the risk and the effects of 
hypoxia and respond to reduced oxygen tension 99. Fetal hemoglobin has a higher affinity for 
oxygen compared to maternal hemoglobin 99. The fetal circulation may adapt to maintain 
adequate blood supply to the brain and heart 99. The fetus will stop moving to decrease the 
oxygen demand 99. In addition, the erythropoiesis will be stimulated in response to elevated 
levels of erythropoietin 97. The levels of erythropoietin seem to be stable during pre-term and 
slightly rise in later gestational weeks 100. The level of erythropoietin starts to rise two to three 
hours after the onset of a moderate to severe hypoxia 74, 75, 101. There are several different 
receptors with affinity to erythropoietin 97. It has been argued that a fast increase and high 
levels of erythropoietin will mainly affect receptors with a low affinity of erythropoietin, 
mediating short-term effects of erythropoietin including anti-inflammation, anti-apoptotic and 
antioxidative effects 97. These effects seem to be neuroprotective 97. It has been shown that 
neonates treated with therapeutic cooling combined with high doses of erythropoietin had 
decreased severity of brain injury than neonates who got therapeutic cooling only 97. Chronic 
hypoxia, lasting for days, leads to a smaller, prolonged increase in erythropoietin 
concentration which will lead to enhanced erythropoiesis, neurogenesis and angiogenesis 97. 
Fetal blood erythropoietin level has a strong correlation to erythropoietin level in amniotic 
fluid 102. The level of erythropoietin in amniotic fluid can possibly differentiate between acute 
and chronic causes of stillbirth with high levels of erythropoietin in amniotic fluid when the 
hypoxic situation has lasted for a long time and normal levels of erythropoietin in amniotic 
fluid when the hypoxia/asphyxia was acute 103.  
2.2.3.1 Relevant difference in erythropoietin concentration 
It is well known that fetal hypoxia is associated with increased levels of amniotic and cord 
blood erythropoietin 74, 97. Erythropoietin levels increased rapidly with acute hypoxia, 
however, stabilized at a slightly increased level with chronic hypoxia 104. In fetal lamb 
exposed to low grade hypoxia, erythropoietin levels increased from a mean of 23 mU/ml to 
145 mU/ml during the first 24 hours, then stabilized at a mean level of 31 mU/L in 7 days 104. 
In a comparison between term pregnancies before gestational week 40+6 and pregnancies 
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from gestational week 41+0 the median erythropoietin levels were 20 U/l and 34 U/L, 
respectively 100. Among normal weight women compared to obese women the erythropoietin 
levels were 25 U/L and 64 U/L, respectively, however including an increased number of 
complicated deliveries 51.  
Median cord blood erythropoietin levels in uncomplicated pregnancies of 20-35 U/L before 
the onset of labor and with an upper limit ranging between 50-60 U/L are considered 
normal74.  
2.2.4 Obesity and placental changes 
Placental analyses can reveal important pathological pathways between mother and fetus. 
Placental analyses are crucial in the evaluation of stillbirth and in the attempt to find the cause 
of stillbirth 105, 106.  
Studies on placental pathology from women with obesity are scarce and results are 
conflicting. A large cohort study showed an increased proportion of placental infarctions and 
signs of chorioamnionitis in term and pre-term placentas from pregnancies complicated by 
obesity 107. It has also been shown that obesity is associated with increased number of 
placental vascular lesions, in uncomplicated pregnancies 108. Obesity has also been associated 
with focal villous immaturity and increased number of capillaries per villous but without 
inflammatory changes 109. However, another study showed increased levels of inflammatory 
mediators but no vascular lesions 110. Several studies have small sample sizes 108-110. Even in 
uncomplicated pregnancies with normal delivery, a healthy and normal-sized infant and a 
healthy woman, there are a substantial proportion of pathological placental lesions 107-109. The 
high proportions of placental lesions in healthy pregnancies, probably reflect that the placenta 
is an organ with large capacity and with a short life-time.  
It has been shown that obese mice have very early changes in the placental transcriptome, 
affecting a number of important genes for angiogenesis and placental development 111. It is 
possible that similar placental changes also in human pregnancies of obese women contribute 
to the elevated risk of complications. 
To our knowledge, there are so far no studies comparing placentas of normal weight and 
obese women with respect to placental lesions possibly leading to fetal chronic hypoxia or 
placental lesions possibly compensating for chronic fetal hypoxia.  
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2.2.5 Placental lesions associated with hypoxia 
The placenta has a high capacity to deliver oxygen. There are several placental lesions 
associated with a hypoxic situation reflecting either, signs of mechanisms to secure the 
oxygen supply or signs of processes impairing the blood flow. These lesions are associated 
with several conditions such as preeclampsia, intrauterine fetal growth restriction, stillbirth 
and preterm birth 112. However, lesions are also found in normal pregnancies and many 
fetuses will be well oxygenated although there are placental lesions associated with chronic 
fetal hypoxia 112. Thus, interpretation of meaning of different placental lesions is not always 
straight forward 112.    
2.2.5.1 Mechanisms behind placental lesions associated with chronic fetal hypoxia 
Placental lesions associated with hypoxia is divided in three groups according to the 
underlying reason for hypoxia. The three groups are; pre-placental hypoxia, decreased utero-
placental supply and post placental hypoxia 113. Pre-placental hypoxia may be present in 
women with anemia and women living at high altitude, the volume of vessels in the villi will 
increase to increase the possibility for oxygen exchange 114. These changes are usually fairly 
uniformly distributed in the placenta 112. Decreased utero-placental supply is a decreased 
perfusion through the spiral arteries, for example when the spiral arteries have not undergone 
normal remodeling. That may result in the same kind of placental changes as pre-placental 
hypoxia, however with focal lesions 112. In both conditions the placenta is often large and the 
ratio between placental weight and fetal weight is increased 113, 115. These lesions are signs of 
compensatory mechanisms due to fetal hypoxia. Post-placental hypoxia occurs when the 
obstruction of the blood flow is distal to the placenta and may for example be due to a 
mechanical obstruction of the umbilical vessels 113. If there is an obstruction in the umbilical 
cord the amount of oxygen in the placenta will increase and angiogenesis in the villi will 
decrease, the newly formed villi will be long and thin with limited branching, called distal 
villi hypoplasia 80.  
Impaired placental oxygen supply leads to increased levels of angiogenic placental factors in 
maternal blood. Increased level of angiogenic placental factors leads to increased placental 
size to be able to support the fetus with adequate amount of oxygen 115. Obese women may 
require an increased amount of oxygen herself, in some cases affecting the placental oxygen 
supply, pre-placental hypoxia, resulting in increased level of angiogenic placental factors 115. 
An increased placental size may be a compensation of a hypoxic situation.  
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In addition, there are placental insults, seen as placental lesions, which impair the blood flow 
and could lead to fetal hypoxia. For example, placental infarctions or placental abruptio could 
lead to both acute and chronic fetal hypoxia.   
2.2.5.2 Placental lesions associated with chronic fetal hypoxia 
There have been different definitions of placental lesions in the obstetric field which have 
made it hard to compare scientific findings and outcomes. A consensus meeting, Amsterdam 
Placental Workshop Group, in 2014 resulted in a document with definitions of different 
placental lesions and an agreement on lesions with adequate scientific documentation to be 
considered as definitive manifestations of chronic hypoxia 116. The definitive lesions which 
could lead to chronic fetal hypoxia include placenta hypoplasia ≤ the 10th percentile for 
gestational age, infarctions, retroplacental bleeding and decidual arteriopathy. Villous 
infarction is the most obvious sign of an event leading to fetal hypoxia and may occur after 
occlusion of a spiral artery. A small peripheral infarction in the placenta of a full-term 
pregnancy is a common finding, probably with limited clinical consequences. However, if 
there are preterm infarctions, central infarctions or if a significant fraction of the placental 
parenchyma is involved there are potential clinical consequences 112, 116. Retroplacental 
bleeding is the pathological sign of a potential placental abruption 112, with the potential to 
cause fetal hypoxia. Decidual arteriopathy seen when the spiral arteries do not remodel and 
widening as they should during early pregnancy, which could lead to impaired blood flow. 
Decidual arteriopathy is seldom found in placental analyses because they are mostly in the 
maternal part of the decidua 112.     
Additionally, there are placental lesions which are signs of compensatory mechanisms of 
chronic fetal hypoxia. Increased placental size may compensate fetal hypoxia as well as 
increased angiogenesis seen as increased number of syncytial knots and chorangiosis 112. 
Chorangiosis is increased number of capillaries in the terminal villi 112. Syncytial knots are a 
marked clustering of syncytial nuclei seen in light microscope.  
2.2.6 Placental lesions associated with stillbirth 
Placentas from pregnancies complicated by stillbirth are in general smaller than placentas 
from pregnancies with live-born infants 105. Increased proportions of signs of both acute and 
chronic inflammation, chorioamnionitis and villitis and signs of retroplacental bleeding are 
associated with stillbirth 105. An umbilical cord that is long for gestational age, a hyper coiled 
umbilical cord and a velamentous or marginal umbilical cord insertion as well as an umbilical 
cord knot and umbilical thrombosis are also associated with stillbirth 105, 117, 118. In addition, 
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fetal vascular thrombosis and placental infarctions are associated with stillbirth. Especially in 
pre-term stillbirths immature villous were more common in the placentas compared with 
placentas from pregnancies with live born infants 119.  
2.3 FETAL SIZE, FETAL GROWTH AND SURVEILLANCE OF FETAL GROWTH 
There is a linear association between maternal BMI and birthweight 80, 81, 120. There are 
different definitions of LGA in different countries. In Sweden LGA is defined as birthweight 
equal to or above the 97th percentile for gestational age and sex (≥2 SD) and SGA is defined 
as birthweight equal to or below the 3rd percentile for gestational age and sex (≤-2 SD) 8. 
Internationally, LGA is usually defined as a birthweight ≥ the 90th percentile for gestational 
age and sex and SGA as birthweight ≤ the 10th percentile for gestational age and sex. The 97th 
percentile may be a more adequate cut-off for defining LGA since previous studies have been 
able to show increased risk of adverse advents at the 97th percentile however not at the 90th 
percentile 9, 121. However, SGA infants with birthweight between the 10th and 5th percentile, 
and also between the 15th and 10th percentile, had markedly increased risks of mortality and 
morbidity even if the risks were even higher among infants with birthweight < 5th percentile 
121, 122.    
Fetal growth is the result of a complex interplay between several factors, e.g. genetics, 
intrauterine environment, maternal constraint, nutrition and placental function. Insulin and 
insulin-like growth factor (IGF) are crucial for fetal growth 123-126. The secretion of fetal 
insulin is one of the key determinants of fetal growth, most prominent during the third 
trimester when the largest increase of fetal weight occurs 123. The Pedersen hypothesis; 
maternal hyperglycemia leads to increased level of glucose passing the placenta, which in 
turn stimulates fetal insulin secretion and fetal growth, is one mechanism behind excessive 
fetal growth 127, 128. IGF-1 has been shown to be a very important prenatal growth factor, 
supported by studies of genetic disorders and by animal models 125, 129. In animal models, 
IGF-1 deficiency results in severe growth restriction and a high postnatal mortality, and for 
humans there is a strong correlation between level of IGF-1 in cord blood and birthweight 125, 
126, 129. There are additional mechanisms, for example leptin, an adipokine, regulating the 
metabolic homeostasis 130. Maternal leptin levels increase during pregnancy, more 
pronounced in pregnancies complicated by obesity probably reflecting an increased leptin 
resistance 130, 131. Leptin affects placental amino acid transport and affects fetal growth by 
increased amounts of nutrients transported over the placenta 130. 
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To be able to take preventive action and make decisions about fetal surveillance during 
pregnancy and mode of delivery, it is important to identify fetuses at increased risk because 
of their size 132. LGA and SGA fetuses are at increased risk of hypoxia/birth asphyxia during 
labor and have an increased risk of mortality 9, 122. However, risks can be reduced if clinicians 
are aware that the fetus is not of appropriate size 133. The most frequently used screening 
methods for identification of SGA and LGA fetuses are based on measurements of fundal 
height. However, measurement of fundal height is imprecise 134, 135. An abnormal rise of 
fundal height will warrant an ultrasound examination and an estimation of fetal weight that is 
repeated every second week if needed. However, primary preventive actions are preferably 
taken before the pregnancy.  
2.3.1 Obesity and large for gestational age infants 
Infants born LGA have increased risks of adverse perinatal outcomes including birth 
asphyxia, shoulder dystocia, and neonatal morbidity 9, 10, 136, 137.  LGA offspring also face 
excess risks of infant death, future obesity, hypertension and type 2 diabetes mellitus 9, 81, 138, 
139. Approximately one fifth of obese women give birth to an LGA infant, defined as 
birthweight equal to or above the 90th percentile 81, 120, 140.  
The pathophysiology behind LGA in obese pregnancies is not fully understood 141. Normal 
pregnancy induces a pro-inflammatory, hyperlipidemic state with increased insulin resistance 
due to the elevated levels of pregnancy related hormones. These metabolic changes during 
pregnancy will be exaggerated if the woman is overweight or obese 41. Several mechanisms 
behind excessive fetal growth in obese pregnancies may be considered 142. Obesity is 
associated with a state of sub-clinical inflammation, impaired insulin signaling, resulting in 
even more pronounced insulin resistance, increased levels of blood glucose and increased risk 
of fetal hyperinsulinemia 32, 142. In addition, obese women have increased levels of lipids; 
increased levels of triglycerides, increased concentrations of low-density lipoprotein and 
increased levels of leptin 41, 143. The high amount of nutrients transported over the placenta 
will contribute to fetal growth and a high level of triglycerides at the same time as high levels 
of glucose and insulin will contribute to increased fetal fat mass 142, 144. High levels of leptin 
could be associated with maternal fat mobilization and an even higher level of available 
nutrients 41.  
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2.3.2 Pregnancy associated plasma protein A and adverse perinatal 
outcome  
Pregnancy associated plasma protein A (PAPP-A) is a proteolytic enzyme, produced in the 
placenta and in several maternal tissues 145. PAPP-A cleaves insulin growth factor binding 
protein (IGFBP), which decreases its affinity to insulin growth factor (IGF) leading to an 
increased level of physiologically active IGF 145.  
PAPP-A is one of the components in the aneuploidy screening in early pregnancy 146. Low 
levels of PAPP-A are associated with an increased risk of several pregnancy complications 
including preeclampsia, SGA and stillbirth. High levels of PAPP-A are associated with risk 
of LGA 66, 147, 148.  
Levels of PAPP-A in early pregnancy are generally lower in women with any type of 
diabetes 149, 150. Women with early onset gestational diabetes have, in general, lower levels of 
PAPP-A than women with late onset gestational diabetes, and women with pre-gestational 
diabetes have lower PAPP-A levels than women with gestational diabetes, indicating an 
association between levels of PAPP-A and degree of maternal glucose intolerance 150.  
2.4 SWEDISH MEDICAL BIRTH REGISTER 
The Swedish Medical Birth register was established in 1973 with the purpose to gather 
information about antenatal and perinatal factors which could affect the health of the infant. 
The Swedish Medical Birth Register has been evaluated several times by comparing original 
medical records with data from the register 151. Approximately 1.4% of infants in Sweden are 
not registered in the Swedish Medical Birth Register 151.  
BMI is available for 73-88% of women, with the higher values for the later years 151. Data on 
parity is valid in 98% of cases of singleton pregnancies. Data on stillbirth or live birth are 
correct to a very large extent 151. Birthweight is recorded to a very high degree. In summary 
the Swedish Medical Birth Register is a validated register with low degree of missing values 
for many variables 151.  
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3 AIMS OF THE THESIS 
The overall aim was to be able to predict LGA and stillbirth among overweight or obese 
women and to find factors contributing to the increased risk of stillbirth among obese women.  
Specific aims:  
Study I  To develop a predictive model for risk of LGA pre-pregnancy and 
in early pregnancy in obese women.  
Study II  To develop a predictive model for risk of stillbirth among 
overweight and obese women in early pregnancy. 
Study III To investigate if fetuses in pregnancies complicated by obesity 
suffer from chronic fetal hypoxia to a higher degree than fetuses 
to normal weight women.  
Study IV  To find placental factors mediating the increased risk of stillbirth 
with increasing BMI.  
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4 MATERIALS AND METHODS  
A brief description of the methods for each study will follow. Comprehensive descriptions of 
the methods and materials are provided in each of the original articles at the end of the thesis.  
4.1 STUDY I 
A register-based cohort study including all singletons born alive at term, without fetal 
anomalies, identified in the first trimester screening data base between the years 2006-2015, 
crosslinked to the Swedish Medical Birth Register and the Swedish Register of Total 
Population, including information on 139 277 pregnancies after exclusions.   
The outcome, LGA, was defined as birthweight ≥ the 97th percentile (two standard deviations 
above the mean) for gestational age and sex 8  
Three different predictive models were constructed; one model for all pregnancies 
complicated by obesity (i.e. both nulliparous and parous women without considering data 
from previous pregnancies), one model for parous obese women (i.e. all women who had at 
least one child before the index pregnancy) and one pre-pregnancy model for parous obese 
women.  
4.2 STUDY II 
A register-based cohort study including all singletons born at gestational week 28+0 or later, 
with women without pre-gestational diabetes, between 2006 and 2015, identified in the first 
trimester screening database (KUB-database), cross-linked to the Swedish Medical Birth 
Register and to the Swedish Register of Total Population. The final study cohort comprised 
145,319 pregnancies, after exclusions. The predictive models were based on all pregnancies 
to women with BMI ≥ 25 and without pre-gestational diabetes.  
The outcome was stillbirth from gestational week 28+0 in singleton pregnancies.  
The predictive model was based on risk estimates from the logistic regression analysis. The 
final model for prediction of stillbirth included predictors significantly associated with 
stillbirth in the multivariable regression model, (e.g. BMI, PAPP-A, maternal age, smoking 
status, the maternal country of birth and parity).  
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4.3 STUDY III 
A prospective cohort study with consecutively collected placentas and cord blood samples 
from 89 women with BMI ≥ 30 and 91 women with BMI 18.5-24.9, all with term, singleton 
uneventful pregnancies. Women with a diagnosis of pre-gestational diabetes, a diagnosis of 
GDM, preeclampsia, hypertension, fetal malformations or intrauterine fetal growth restriction 
defined as a birthweight ≤ 10e percentile for gestational age and sex 8 were excluded.  
Immediately after delivery cord blood was sent to a research laboratory, Studiecentrum at 
Karolinska University Hospital Solna, for analysis of erythropoietin. The placentas were sent 
to the Department of Perinatal Pathology at Karolinska University Hospital, Huddinge. Two 
senior perinatal pathologists performed the placental analyses following a standardized 
protocol, blinded for maternal BMI 152. Placenta samples were prepared for histopathological 
examination with focus on lesions associated with chronic fetal hypoxia including: placental 
infarction, placental abruption, decidual arteriopathy, placental size, chorangiosis and 
proportion of syncytial knots.  
Linear regression analyses were used to assess the impact of maternal BMI on erythropoietin 
concentrations, adjusted for the potential confounders maternal age and parity and in 
addition, the mediators gestational age 49, 100, 153 and mode of delivery. There were outliers 
with high erythropoietin concentrations, which were scrutinized to be able to find a reason for 
that.   
Placental lesions were analyzed one at a time and in addition, two composite variables 
associated with chronic fetal hypoxia. One with lesions which could lead to chronic fetal 
hypoxia; placental hypoplasia, retroplacental bleeding, infarctions and decidual arteriopathy   
and one composite variable of lesions which could be compensatory of chronic fetal hypoxia; 
placental hyperplasia, chorangiosis and increased number of syncytial knots.  
4.4 STUDY IV 
A case control study with all singleton stillbirths, without pregnancies complicated by pre-
gestational diabetes or GDM and without major fetal malformations, diagnosed at term with a 
BMI ≥ 30 or a BMI 18.5-24.9 identified in the Stockholm Stillbirth database between 2002 
and 2018 were selected as cases, n=87 and n= 264 respectively. Information about the 
pregnancies and maternal characteristics have been prospectively collected for all cases of 
stillbirth. All placental analyses were reevaluated by two senior perinatal pathologists.   
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Placentas from women with live-born infants, the controls, were collected from 106 full term 
singleton pregnancies with BMI ≥ 30 consecutively, and 113 pregnancies with BMI 18.5-
24.9 consecutively at Södersjukhuset, Stockholm, Sweden. Placentas were analyzed by two 
senior perinatal pathologists following a standardized protocol, blinded for maternal BMI and 
other maternal characteristics 152.  
Frequencies of the placental variables and birthweight were compared between cases and 
controls stratified by BMI. Since controls were selected with a pre-determined distribution of 
obesity, the proportion of obese women among the controls was corrected by weighting, to 
ascertain an equal proportion of obese women as in the general population. The true 
proportions of normal weight women and obese women in the Stockholm region were 
collected from the National Board of Health and Welfare 154. A logistic regression with BMI 
as exposure and stillbirth as outcome was conducted. Potential confounders, i.e. maternal age, 
smoking habit, parity and maternal country of birth were added to the logistic regression. 
Different groups of placental variables, indicating potential mediators of the effect of BMI on 
stillbirth, were added to the adjusted logistic regression analysis. These were: A) variables 
indicating abnormal umbilical cord: velamentous insertion, umbilical thrombosis, umbilical 
knot, an umbilical cord long for gestational age and a high coiling index, B) variables 
indicating inflammation, chorioamnionitis,  and C) variables indicating maternal circulatory 
disorders, retroplacental bleeding, infarcts and placental hypoplasia 105, 116. 
5 METHODOLOGICAL CONSIDERATIONS 
5.1 STUDY I AND STUDY II 
The validity of a study might be threatened by systematic errors like selection bias, 
misclassification and confounding bias. Systematic errors will continue to exist regardless of 
the size of the sample if the study design is not appropriate. In addition, the reliability of a 
study might be threatened by random errors. However, random errors will decrease with the 
size of the sample. Calculating the P-value and the confidence interval are methods to assess 
the degree of uncertainty due to random errors.  
5.1.1 Systematic errors  
5.1.1.1 Selection bias  
Study I and study II were based on the first trimester screening database, (KUB-database). 
PAPP-A has been advocated as a valuable predictor for both LGA, SGA and stillbirth 155. 
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The first trimester screening database (KUB-databasen) collects a large part of women 
undergoing the first trimester screening in Sweden which include PAPP-A and b-hCG levels 
in early pregnancy. That was the reason to base study I and study II on the first trimester 
database. However, the first trimester database suffers from selection bias. When first 
trimester screening was first offered it was only women 35 years or older or with a special 
reason or a special request who were offered the first trimester screening. Rather soon the 
population who were offered the first trimester screening increased, especially in the 
Stockholm region. Guidelines about offering first trimester screening as well as midwives 
educated in first trimester screening differ throughout the country. Women in the first 
trimester screening database have a higher educational level, higher age and lower BMI than 
the general obstetric population in Sweden 12. Hence, the first trimester database is based on a 
selected population. Incidences and absolute numbers will be affected by the selection bias. 
When performing a prediction, the area under the curve (AUC) will be based on the strength 
of the associations between the predictors and the outcome. If the strength of the associations 
differs in the sample and the general obstetric population the AUC will be biased. A weaker 
association in the sample would have biased the AUCs downwards and a stronger association 
would have biased the AUCs upwards (towards 1). However, it is not obvious whether the 
predictor-outcome associations are different in our sample compared with the general 
obstetric population. The absolute numbers of stillbirth are lower in our sample, however the 
ratio between incidence of stillbirth among normal weight women and incidence of stillbirth 
among obese women is in line with previous studies 3. Further, predictions generally become 
better when the predictors have high variability (e.g. include both low and high values), the 
relatively low variability of predictors in our sample are likely to have biased the AUCs 
downwards (towards 0.5). In both study I and study II the predictions are made for certain 
BMI levels, ≥ 30 and ≥ 25, respectively. In study I the AUC would have increased if women 
over all BMI levels were included in the predictions in accordance with the reasoning above. 
In study II the associations between the potential predictors and the outcome were non-
existing or very weak among the normal weight women, in contrast to in women with BMI ≥ 
25. Because of that the AUC decreased for predictions including women from all BMI levels 
in study II. The variables associated with stillbirth among women with BMI ≥ 25 that were 
not associated with stillbirth among normal weight women were BMI, PAPP-A, maternal 
age, smoking status, maternal country of birth and parity.  
If I would have re-done study I and study II, I would not have restricted the data to 
pregnancies with known value of PAPP-A. In that case I would have had data from the 
Swedish Medical Birth register which would not have suffered from selection bias. It would 
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then have been possible to do the predictions among un-selected pregnancies and compare 
the results between these two samples. The associations between PAPP-A and LGA and 
PAPP-A and stillbirth are weak, however with low P-values since there is a large sample size. 
The predictive capacity of PAPP-A is weak for LGA, SGA and stillbirth 66, 147, 156-159.      
5.1.1.2 Cross-validation  
When doing predictions confounding is not a problem since we are not measuring a causal 
effect. However, there are other concerns. It is possible to over-fit the model to the data, 
which would lead to a very good prediction in our specific sample, but not in a new random 
sample. To obtain an unbiased estimate of the predictive accuracy, the dataset was randomly 
divided in two parts where one part was used to fit the model and the predictions were made 
in the other part, a cross-validation. The cross-validation was done 1000 times for all the 
different predictive models in study I and study II. For predictions of LGA the results were 
virtually the same after cross-validation, indication a good internal validity. After cross-
validation for predictions of stillbirth the AUC slightly decreased. 
5.1.1.3 Misclassifications  
Study I and study II were based on the first trimester screening database cross-linked with the 
Swedish Medical Birth register. The exposure was BMI and the outcomes were LGA and 
stillbirth, respectively. BMI is based on measured weight during the first trimester and self-
reported height. Self-reported height may be overestimated and may be overestimated to a 
higher degree among overweight and obese women. In addition, initially there were 
approximately 400 cases with extremely high BMI values. Height and weight had been 
switched when BMI was calculated. By calculating BMI from the height and the weight 
variables these extreme values disappeared. The correct BMI values in cases with 
misclassified, extremely high BMI values, varied between 15 and 38. If this would not have 
been corrected it would have had the potential to dilute the results since the misclassification 
was unrelated to the true BMI. The LGA variable is easily counted from the birthweight, the 
gestational age and the infants’ sex, which are all reliable variables with almost no missing 
values. Stillbirth is also a reliable variable, with a low degree of missing value 151. The 
Swedish medical birth register is a reliable and validated source 151. The risk of 
misclassification is low in both study I and study II. If there were misclassifications anyway, 
they were probably random and would then have the possibility to dilute the results.         
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5.1.2 Random errors  
Random errors occur as an imbalance between the compared groups caused by chance. 
Random errors will decrease with increased size of the sample. Study I and study II are based 
on large samples and random errors was not a significant problem. Both the P-values and the 
confidence intervals are used to show the precision of the results and the possibility of pure 
chance as a cause of the results. The P-values are a measurement of the possibility to have the 
same or a more extreme result if there were no real differences between the compared groups 
(i.e. if the null-hypothesis was true). 95 % of the confidence intervals will contain the true 
parameter value, if the trial was hypothetically repeated and the confidence interval was 
recalculated for each trial. Since the sample was large even small differences between groups 
became strongly significant. The predictive capacity is mainly based on the magnitude of the 
effect of the associations and not on the P-value.  
5.1.3 External validity 
External validity refers to the possibility to apply the conclusions from the study also to other 
populations. The external validity in study I and study II will depend on the possible 
differences in effect by the predictors on the outcomes in the sample compared to another 
populations. E.g. will an increase in BMI from 30 to 32 increase the risk of giving birth to an 
LGA infant to a higher or lower degree in the general obstetric population than in the sample? 
This question is hard to answer. However, there is no obvious reason to believe that there 
would be a substantial difference. The risk of stillbirth among overweight or obese women 
divided with the risk of stillbirth among normal weight women (2.6/1.6=1.6) is in line with 
results from a large meta-analysis 3.   
5.2 STUDY III AND STUDY IV 
5.2.1 Power calculation 
Study III compared differences in proportion of placental lesions. Previous researchers have 
been reporting conflicting results 107-109. A power calculation depends on assumptions about 
differences between the compared groups. Because of previous conflicting results these 
assumptions were hard to make and a power calculation hard to do.  
Cord blood erythropoietin levels associated with chronic fetal hypoxia have been suggested 
to increase 10-15 U/L in different studies 100, 104. Erythropoietin concentration of <30 U/L is 
suggested as a normal erythropoietin concentration 97. A power calculation to be able to have 
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80% chance to find a difference of mean erythropoietin level between 30 U/L and 40 U/L 
gives a sample of 60 persons in each group.   
Study IV was a case control study with a fixed number of cases collected from the Stockholm 
stillbirth database. It would not have been possible to collect more cases. Hence, the reason to 
conduct a power calculation was not to be able to collect enough cases, it was to evaluate the 
possibility to be able to have a reasonably good chance to answer the research question. The 
aim of study IV was to explore the potential mediating role of placental lesions on the causal 
pathway from maternal obesity to term stillbirth. Towards this aim the association between 
maternal obesity and term stillbirth was compared before and after adjusting for placental 
lesions.  
5.2.2 Systematic errors 
5.2.2.1 Selection bias 
For study III placentas and cord blood samples were collected at the delivery ward and at the 
unit of elective cesarean section. This sample of women and placental analyses were, in 
addition, used as controls in study IV. Elective cesarean sections are pre-planned. From the 
day the inclusion started almost all women who fitted the inclusion criteria were included. 
One woman was not willing to participate. However, the proportion of normal weight women 
was higher, and normal weight women were included in a shorter time-period than women 
with BMI ≥ 30. Since the cesarean sections were elective it was possible to know that only a 
small number fitting the inclusion criteria was missed for inclusion. The faster inclusion of 
normal weight women is not likely to have affected the sampling. Spontaneous labors are un-
planned. There had been information distributed about the intended inclusion of women, 
however the probability to be included in the study was higher when the author was present at 
the delivery ward. There is a higher probability that a woman with a labor lasting for many 
hours should be identified and included than a woman who only was present a short time at 
the delivery ward, a difference which may have been even more pronounced among normal 
weight women since it was easier to remember to include women with BMI ≥30. If a larger 
proportion of normal weight women had a longer duration of labor, it may have increased 
some of the erythropoietin concentrations. In that case, it would lead to a decreased difference 
between normal weight and obese women and it would have decreased the magnitude of the 
results. Length of labor would not affect the results of the placental analyses. Nulliparous 
women, however, generally have labors lasting for a longer period of time and could have 
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been overrepresented. Normal weight women were included during a shorter time-period 
than women with BMI ≥ 30.  
The erythropoietin levels may have been affected by mode of delivery, with the highest levels 
among the vaginal births. Even an un-complicated vaginal delivery may cause fetal hypoxia 
which could lead to increased erythropoietin production 74. There was a tendency to a longer 
duration of time from cervical dilatation of 7 cm to delivery among normal weight women, 
which could be explained by a higher number of nulliparous women among the normal 
weight women. The longer duration of labor may have increased erythropoietin levels among 
normal weight women, in that case the difference of mean erythropoietin level between 
normal weight and obese women would decrease. However, both parity and mode of delivery 
were adjusted for in the analyses. The odds ratio for BMI without mode of delivery in the 
model was 0.9745 and was virtually the same with mode of delivery in the model OR 0.9735, 
indicating that the effect of obesity on level of erythropoietin was not depending on mode of 
delivery. The association between BMI and erythropoietin was, in addition, analyzed 
stratified on mode of delivery. Inevitably, stratification by mode of delivery leads to analyses 
in smaller parts of the data and a larger statistical uncertainty. However, there was a 
significant and borderline significant association between BMI and erythropoietin among 
women with vaginal delivery and women with elective cesarean section, respectively (P-
value 0.04 and 0.08, respectively).  
Study IV compared placental lesions from pregnancies with stillborn and live-born infants 
stratified on BMI. The women with live-born infants, the controls, were almost the same as in 
study III and their selection was discussed above, however placenta pathology should not 
have been affected by mode of delivery. The Stockholm stillbirth database was used to 
identify cases, women with stillborn infants. The Stockholm stillbirth database contains 
virtually all cases of stillbirth in the Stockholm region from 1998, numbers controlled by 
comparison of numbers reported from the Board of Health and Welfare 154. All cases of term 
stillbirth without a diagnosis of diabetes and with BMI 18.5-24.9 or BMI ≥ 30 from Jan 1st, 
2002 were included in study IV. The reason to exclude cases of stillbirth before 2002 was an 
increased number of missing values and difficulties with reaching the placenta analyses 
which were crucial in this study. There were only ten placental analyses missing among the 
cases, four in pregnancies with obesity and six in pregnancies with normal weight. The 
criteria for GDM changed in 2016 and there may be cases of stillbirth, who would have been 
diagnosed with GDM today, however did not get the diagnosis the year they gave birth. 
Previous studies have shown that women with diagnosed GDM do not have an increased risk 
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of stillbirth as compared to women without GDM 160, 161. However, previous studies have also 
shown that women with increased risk of undiagnosed GDM, (i.e. at increased risk of GDM 
without a diagnosis) are at increased risk of stillbirth compared to women without GDM, also 
when adjusted for BMI 160. One possible explanation could be that women with a diagnosis of 
GDM are closely monitored and their glucose concentrations are treated to become as close 
to normal as possible, which could compensate for the increased risk.  
There is no selection bias among women with stillborn infants, since all these women were 
included. The controls were collected during a much shorter time period. The proportion of 
obese women has increased during the time of case collection 12. The incidence of stillbirth 
has been stable 65. Hence, year of birth is not a confounder, only taking exposure and 
outcome into consideration. The pathways between BMI, stillbirth and year of birth are 
illustrated in figure 4. If these assumptions are correct the adjustment for year of birth in the 
logistic regression with obesity as exposure and stillbirth as outcome would not affect the 
estimate of obesity in relation to stillbirth, however, increase the P-value. The greatest “risk 
factor” of stillbirth becomes year of birth since no infant was live born between 2002 and 
2017 among cases and controls in our sample. However, this risk factor is an artefact of the 
study design and in the adjusted analysis, risk estimates remained stable also after adjustment 
of year of birth.        
  
Figure 4: A direct acyclic graph (DAG) is a tool to visualize potential causal pathways. In 
this case the DAG is used to visualize the pathways between BMI, stillbirth and year of birth. 
Prevalence of obesity has increased during the years of the study; however, incidence of 
stillbirth has been stable.  
However, there are other circumstances which have changed during these years, which would 
have been valuable to be able to adjust for. The most important change may be the stricter 
diagnostic criteria for GDM. There may be cases who would have been diagnosed with GDM 
in year 2018 however, were not diagnosed with GDM the year they gave birth. In this case 
GDM could be a potential mediator for the effect of BMI on the risk of stillbirth. Since the 
risk of misclassification is largest among cases, this potential misclassification will be 
differential. It could potentially affect the effect of BMI on stillbirth.   
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When conducting the logistic regressions in study IV, there was a positive association 
between parity and stillbirth. However, it is well known that nulliparity increases the risk of 
stillbirth, hence the association should have been negative 26. One could wonder if there was a 
selection bias among the controls or if the risk associated with nulliparity differs between 
different BMI categories or with different gestational ages among stillbirths. Study IV include 
term stillbirths and certain BMI categories. However, in the whole Stillbirth database, all 
BMI categories included, there are 39% nulliparous women with term stillbirths and 37% 
nulliparous women with pre-term stillbirth and 45% nulliparous women with term stillbirth 
among normal weight women. Among controls in study IV, there were 55% nulliparous 
normal weight women and 42% nulliparous obese women. The controls comprised a small 
sample of women with potential of random errors. However, according to the Board of 
Health and Welfare there has been a stable level of 48% nulliparous women among normal 
weight women over the past years 154. Hence, also compared to all women in the target 
population there was a positive association between parity and stillbirth among normal 
weight women. Among obese women the proportion of nulliparous women, according to the 
Board of Health and Welfare has been 37% the last years 154. Among obese women with 
stillborn infants there were 38 % nulliparous women, hence compared to all obese women in 
the target population there was a negative association between parity and stillbirth, as 
expected, although weak.  
The association between maternal age and stillbirth was negative in the logistic regression in 
study IV. It is known that high maternal age increases the risk of stillbirth as well as low age. 
It is not possible to get the median age in different BMI categories from the Board of Health 
and Welfare, without a special application. Median age of women giving birth to their first 
child in Stockholm was 30.4 years in 2018, according to the Board of Health and Welfare 154. 
Median age in the Stockholm stillbirth database was 31.8 years, both nulliparous and parous 
women included, no difference in maternal age between stillbirths at term and preterm. In our 
sample of women, both nulliparous and parous women giving birth at Södersjukhuset, a 
median maternal age between 32-33 years does not seem unlikely. However, cases of 
stillborn infants were collected during a period of 16 years and median age among women 
giving birth have increased during the years. Taken together, the controls consist of a small 
sample which implicates an increased risk of imbalance due to pure chance, however, without 
obvious signs of selection bias. 
A possible explanation of the opposite direction of the association between parity and 
stillbirth and between maternal age and stillbirth could be a higher degree of surveillance 
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among nulliparous women and older women. The knowledge about risk factors among older 
women and nulliparous women may have influenced guidelines in a way to compensate for 
the increased risks, figure 5. Nulliparous women have a larger number of antenatal controls 
and maternal age is taken into consideration when discussing possible induction of labor.  
 
Figure 5: BMI has a positive association with stillbirth. Nulliparity is a confounder with a 
negative association with BMI and a positive association with stillbirth. However, nulliparity 
could have a positive association with surveillance and surveillance a negative association 
with stillbirth, protecting nulliparous women and potentially changing direction of the overall 
association between nulliparity and stillbirth. 
 
5.2.2.2 Confounders and mediators 
 
Figure 6: DAG for the causal pathways in study III: gestational age, gestational hypertension 
and mode of delivery were mediators and maternal age, smoking habit, country of origin and 
parity were potential confounders.  
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A DAG is a tool to visualize potential causal pathways, which can be used to select 
confounders to adjust for in the statistical analysis 162. Confounding is an absolute concept, 
defined as the presence of common causes of the exposure and outcome 163. Confounder is a 
relative concept defined as “the common causes of exposure and outcome that, were they all 
measured, would be sufficient to adjust for confounding” 163. Which variables we may 
consider as confounders thus depend on which other variables we have adjusted for. A DAG 
was used to visualize the causal pathways in study III, figure 6. Gestational age was a 
mediator on the pathway from BMI to concentration of erythropoietin. Mode of delivery was 
a mediator, fixed by study design and therefore adjusted for in the analyses. Gestational 
hypertension was also a mediator. However, the final analyses were not adjusted for 
gestational hypertension since the adjustment for gestational hypertension did virtually not 
affect the association between BMI and concentration of erythropoietin or the association 
between BMI and placental variables. The analyses were also adjusted for maternal age and 
parity, two potential confounders. However, the final analyses were not adjusted for country 
of birth, educational level or smoking, which were also potential confounders. Adjustment for 
country of birth, educational level and smoking did not affect the associations between BMI 
and concentration of erythropoietin or BMI and placental variables.   
 
Figure 7: A DAG to visualize the causal pathways in study IV. Parity and gestational 
hypertension were mediators whereas maternal age, smoking and country of birth were 
potential confounders. Gestational age was a collider since the delivery will be induced after 
the diagnosis of stillbirth. Placental variables were mediators adjusted for in order to evaluate 
their effect.  
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A DAG was used to visualize the causal pathways in study IV, figure 7. It is well known that 
there is a causal pathway from maternal BMI to stillbirth 3. To secure that the group of 
women with BMI > 30 was large enough, controls were collected specified on BMI. The 
proportion of obese women among the controls was corrected by weighting, to become equal 
to the proportion of obese women in the general population. Numbers of deliveries stratified 
on BMI was collected from the Board of Health and Welfare 154. A logistic regression was 
conducted adjusted for the potential confounders, parity, country of birth, maternal age and 
smoking status. There was virtually no difference when adjusting for the potential mediator 
gestational hypertension, hence this was not done in the final analyses. Country of birth was 
used as a dichotomous variable. The sample was small, and it would have been hard to draw 
any conclusions from a more divergent variable. However, one could argue that 
categorization or dichotomization of variables will lead to loss of information, which in turn 
may lead to loss of power 164 and/or residual confounding 165. The effect of BMI on stillbirth 
decreased slightly after adjusting for parity, county of birth, maternal age and smoking status. 
Pathological placental signs were mediators on the casual pathway between BMI and 
stillbirth. The analysis was adjusted for different groups of placental variables, i.e. umbilical 
cord abnormalities, chorioamnionitis and signs of maternal circulatory disorders. The 
adjustment for different groups of placental variables was done to be able to evaluate which 
proportion of the effect of BMI on stillbirth could be mediated by that group of placental 
variables.  
5.2.2.3 Misclassification 
There may be inter-individual and intra-individual differences in classifying placental lesions, 
which could lead to misclassifications (8). The two senior perinatal pathologists who did the 
placental analyses discussed the classifications in case of uncertainty and came to a 
conclusion. BMI was blinded to the perinatal pathologists which would make the potential 
misclassifications non-differential (i.e. the same risk of misclassification among exposed and 
non-exposed). The misclassifications would then possibly dilute the results. Data on maternal 
and infant characteristics came from the antenatal records. There is a risk of misclassification 
in the records, and in addition a risk of misclassification during the work of variable 
extraction. However, these misclassifications would be non-differential with the possibility to 
dilute the results and would not force the results in any specific direction. The variable 
“educational level” was extracted from the antenatal records and was only noted as type of 
occupation from the beginning. This variable was not completely reliable, since it is not 
always obvious which educational level is hidden behind a certain occupation. The variable 
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“maternal country of birth” was also extracted from the antenatal records. Country of birth 
was the variable with largest proportion of missing values both in study III and study IV, in 
study IV both among cases and controls. Since there were 15% missing values for “country 
of birth” in study IV multiple imputation was used to predict the value of missing variables 
based on the other variables. The multiple imputation was used for all missing values in all 
variables used in the logistic regression. The analyses were re-run with multiple imputation 
with virtually the same results.  
5.2.3 Random errors  
Study III and study IV were small studies with potential problems with random errors. 
Estimates derived from a study with a small sample size will have wider confidence intervals 
and larger P-values indicating the larger degree of statistical uncertainty. In study III there 
were wide confidence intervals for the linear regressions of the effect of BMI on 
erythropoietin concentration. In study IV there were wide confidence intervals in general and 
especially for the measurement of difference in effect of obesity on stillbirth when different 
groups of placental variables were added. The small sample size is one reason for that. 
Another reason is that the proportion of difference of effect of obesity on stillbirth includes a 
division, which will amplify the degree of uncertainty. 
5.2.4 External Validity  
There are no obvious reasons for the results of study III not to be valid in other comparable 
populations. However, small studies need other studies pointing in the same direction in order 
to be able to provide solid evidence. Study III is a rather small study in which the results 
constitute a small piece in a large puzzle. The Stockholm Stillbirth database is unique in 
number of cases. It includes virtually all stillbirths in the Stockholm region since 1998. One 
limitation with study IV is the selection of cases over long time. However, with such a rare 
outcome, collection of cases over time is necessary. The target population in study IV was all 
women giving birth in the Stockholm region during 2002-2019. There are no obvious reasons 
that the results from study IV would not be valid for other comparable populations. However, 
it is unclear to what degree changes over time occurred and what implications that could 
have.   
6 RESULTS 
A brief summary of the results for each study will follow. A more comprehensive description 
of the results is provided in each of the original articles added at the end of the thesis.  
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6.1 STUDY I 
There were in total 12 704 pregnancies from 11 580 unique women with BMI ≥ 30 in the 
study cohort and the prevalence of LGA, defined as birthweight ≥ the 97th percentile, was 8.5 
% (n=1 078). In normal weight women as well as women with BMI ≥ 30, the median PAPP-
A values were higher in case of an LGA infant than if the infant was non-LGA.  
The final prediction for the pre-pregnancy model in parous women with BMI ≥ 30 had an 
AUC for the ROC curve of 0.80 (95% CI; 0.78 to 0.82), with a sensitivity of 46 % at a fixed 
90% specificity. The final prediction of the predictive model for LGA, in early pregnancy, in 
parous women with BMI ≥ 30 had an AUC for the ROC curve of 0.81 (95% CI; 0.79 to 
0.82), with a sensitivity of 48 % at a fixed 90% specificity. The AUC for the ROC curve for 
the final predictive model for all women with BMI ≥ 30 (including both nulliparous and 
parous women) was 0.66 (95% CI; 0.64 to 0.67) with a sensitivity of 21 % at a fixed 90% 
specificity 
Results remained essentially unchanged when models were re-run taking all possible two-
way interactions into account and in the cross-validation procedure. 
6.2 STUDY II 
There were in total 45,859 pregnancies from 41,010 unique women with overweight or 
obesity and without pre-gestational diabetes. The prevalence of stillbirth was 2.6/1000 births 
in pregnancies complicated by overweight/obesity and 1.6/1000 births in normal weight 
women. The median gestational age at stillbirth was 37 weeks both in pregnancies 
complicated by overweight or obesity and in normal weight pregnancies. For the whole group 
of pregnancies with stillborn infants, the median PAPP-A levels were lower, and the 
proportion of SGA markedly increased as compared to pregnancies with live born infants. 
The potential predictors BMI, smoking status, maternal age, parity, maternal region of birth 
and preeclampsia were all significantly associated with stillbirth among women with 
overweight or obesity, however they were not associated with stillbirth in pregnancies of 
women with normal weight. The AUC for the ROC curve of the final predictive model was 
0.69 (95% CI 0.64-0.74). The sensitivity was 28 % at a fixed 90% specificity. The AUC after 
the cross-validation procedure for the final predictive model was 0.65. 
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6.3 STUDY III 
Median BMI among lean and obese women were 22.2 kg/m2 and 32.7 kg/m2 respectively. A 
larger proportion of obese women were born outside Sweden compared to normal weight 
women.  
The adjusted linear regression analysis showed a significant positive association between 
maternal BMI and cord blood erythropoietin concentration, P-value 0.01. Normal 
erythropoietin cord blood concentrations < 30 U/L (P-value 0.01) were significantly more 
frequent in offspring of lean mothers, in the adjusted logistic regression. The adjusted linear 
regression for BMI on erythropoietin concentration stratified on mode of delivery showed a 
significant positive association among women with vaginal delivery, (P-value 0.04) and a 
borderline significant association for women with elective cesarean section (P-value 0.08).  
There were nine pregnancies with erythropoietin concentrations above 100 U/L. Six of those 
had a BMI ≥30, except from BMI they had all uncomplicated, normal pregnancies. Seven of 
those women had a vaginal birth and five were primiparous. Five women gave birth in 
gestational week 41+0 or later. The arterial cord blood pH was between 7.14 to 7.20 in four 
cases. None of these infants had a cord blood pH < 7.14. All infants had a birthweight 
appropriate for gestational age. 
Placentas to women with BMI ≥ 30 had significantly longer cords for gestational age. There 
were no differences comparing placentas from obese and lean women with respect to 
placental lesions associated with chronic hypoxia.  
6.4 STUDY IV 
The Stockholm stillbirth database contains information on 1,694 stillbirths delivered between 
2002 and 2018. After exclusion of fetuses with major malformations, multiples, stillbirths 
diagnosed before gestational week 37+0 and fetuses to mothers with diabetes, our final cohort 
included 531 cases. 91 of these were born to obese women and 270 to women of normal 
weight. There were four cases of stillbirth to obese women with missing placenta and another 
six cases of stillbirth to normal weight women with missing placenta. In total there were n=87 
cases of stillbirths complicated by maternal obesity and n= 264 stillbirths to women of 
normal weight. 
A long umbilical cord was more common among obese women compared to normal weight 
women. A long and hyper coiled umbilical cord, vasculitis and umbilical cord thrombosis had 
a stronger association with stillbirth in obese women than in normal weight women. 
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Velamentous or marginal cord insertion were more common among stillbirths to obese 
women than in stillbirths to normal weight women. Causes of term stillbirth according to the 
Stockholm stillbirth classification 61 did not differ between pregnancies of normal weight 
women and obese women.     
When the crude logistic regression was adjusted for the potential confounders maternal age, 
parity, country of birth and smoking, there was a reduction of the effect of obesity on the risk 
of stillbirth. Placental variables, potentially mediating the effect of obesity on the risk of 
stillbirth were added to the adjusted logistic regression analysis, one group at a time. When 
umbilical cord abnormalities were added to the logistic regression, the effect of obesity on the 
risk of stillbirth decreased with 38 % (CI 0.01-2.17), from OR 1.83 (CI 1.09-3.12) to OR 1.45 
(CI 0.83-2.56) and the risk of stillbirth was no longer significantly increased. When 
chorioamnionitis was added to the logistic regression model, there was a 15 % (CI -0.02-
0.67) reduction of the effect size, OR 1.68 (CI 0.99-2.88), with a borderline significant 
association between obesity and stillbirth. Signs of maternal circulatory disorders did not 
impact the effect of obesity on the risk of stillbirth. In total, for the logistic regression 
adjusted for confounders, there were 20 % of observations with missing values. Data on 
maternal country of birth was missing in 15 % of the women, parity was missing in 8 % of 
women, maternal age in 0.8% of women and information on smoking habits was missing in 
0.5% of women. Thus, all analyses were re-run with multiple imputation of all missing data 
with virtually the same results, not shown.  
7 RELATED FINDINGS 
7.1 STUDY I AND STUDY II 
A low level of PAPP-A probably reflects an impaired placentation 150.  It has been argued that 
PAPP-A is a valuable predictor for both SGA, LGA and stillbirth 150, 155. It is true that PAPP-
A has a strong statistical association with these outcomes in large populations 156. However, 
how valuable a predictor is, depends on the strength of the association, not only how certain 
the association is. The normal distribution of the mean level of PAPP-A has a discrete shift to 
the left for SGA infants and stillborn infants and a discrete shift to the right for LGA infants, 
figure 8. There is no obvious cut-off level in the concentration of PAPP-A associated with 
LGA or stillbirth. A strong association between the predictor and the outcome is needed for a 
valuable prediction. The associations between PAPP-A and the outcomes SGA, LGA and 
stillbirth do not include an obvious cut-off level and the associations are weak. The 
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possibility to predict SGA is not higher in comparison to the possibility to predict LGA, 
according to our data. The value of PAPP-A as a predictor in these situations is limited 66, 147, 
158, 159, 166.  
 
Figure 8: Distribution of PAPP-A concentration during first trimester among non-LGA 
infants and LGA infants, median 1.03 and 1.14 respectively and mean 1.19 and 1.31 
respectively. A weak but strongly significant association without a cut-off for the outcome. 
Hence, PAPP-A is a weak predictor.  
 
In general, the level of PAPP-A is lower among women with overweight or obesity, P-value 
< 0.001, however the effect was small. In general, the distribution of PAPP-A levels was 
narrower among obese women than among normal weight women. Decreased levels of 
PAPP-A have also been reported in pregnancies with maternal diabetes. Both among women 
with diabetes and women with obesity there were an association between PAPP-A 
concentration and LGA infants 150. Abnormal glucose metabolism may negatively impact 
placentation by influencing trophoblast invasion 167 and it has been suggested that the 
concentration of PAPP-A may reflect the degree of maternal glucose intolerance with the 
lowest concentrations among women with diabetes type 1 and gradually values closer to the 
normal among women with diabetes type 2, early on-set GDM and late-onset GDM 150. Thus, 
it may be speculated that the lower levels of PAPP-A observed in women with diabetes 
and/or BMI ≥ 30 reflect a suboptimal placentation 150. This is in line with the finding of high 
rates of LGA infants in diabetic pregnancies with tight glycemic control at time of conception 
168. The increased levels of PAPP-A in pregnancies with LGA infants may reflect an 
undisturbed placentation and as a result of an undisturbed placentation in combination with 
increased levels of blood glucose later in pregnancy, an increased risk of an LGA infant. It is 
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possible that insulin resistance in non-diabetic pregnancies with BMI ≥ 30, with only slightly 
elevated glucose levels affect placentation and PAPP-A levels.   
The risk of giving birth to an LGA infant was significantly decreased if the woman had a 
lower BMI at the start of the next pregnancy (OR 0.9 CI 0.83-0.99, P-value 0.04), in line with 
earlier studies 24.   
In study II the associations between the potential predictors and the outcome were non-
existing or very weak among normal weight women, in contrast to women with BMI ≥ 25. 
The predictors BMI, PAPP-A, smoking status, maternal age, parity, maternal region of birth 
and pre-eclampsia were not statistically associated with stillbirth among normal weight 
women, however among overweight or obese women. One can speculate about the reasons 
for this difference. One explanation could be that risks increase when they are added, 
however there was only a significant interaction between BMI and parity and no other 
significant interactions between predictors and BMI. Another explanation could be that obese 
women are handled different than normal weight women or that the extra burden of obesity 
does not lead to increased surveillance in sufficient degree.  
7.2 STUDY III AND STUDY IV 
Placental hypoplasia and placental hyperplasia were defined as a placental weight <10th 
percentile and placental weight > 90th percentile for gestational age, respectively, according 
to a well-known and well-used table for placental weight 169. There was a high incidence of 
placental hypoplasia among both normal weight and obese women, approximately 25 % and 
21 %, respectively. The table of placental weights and their percentiles was made in the USA 
during the 1990s, based on 787 placentas of different gestational age 169. Either the table of 
placental weights is not reliable for conditions in Stockholm or Sweden or our material was 
biased in some way we cannot understand, with a much larger proportion of placental 
hypoplasia than it should be among uncomplicated pregnancies, both among normal weight 
and obese women. In addition, there was a large proportion of pathological placental lesions 
among normal weight women with uncomplicated pregnancies, however, this was in line 
with earlier studies 107, 108. The fact that even an uncomplicated pregnancy may have a large 
proportion of pathological placental lesions needs to be considered when evaluating placental 
lesions.  
There was a strong association between gestational age and erythropoietin among term 
pregnancies, figure 9. The association between gestational age and erythropoietin was un-
affected by adjustment of potential confounders; i.e. maternal age, BMI, pregnancy induced 
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hypertension, parity and mode of delivery. The finding was in accordance with a recent study 
from Finland 100.   
 
Figure 9: Erythropoietin and gestational age. Red dots: elective cesarean section, blue dots: 
vaginal birth. Linear regression adjusted for maternal age, BMI, mode of delivery, gestational 
hypertension and parity.  
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Figure 10: Gestational weight gain had a negative association to erythropoietin 
concentration. Blue dots are obese women and red dots are normal weight women.  
When gestational weight gain was added to the linear regression of BMI and erythropoietin, 
there was a significant negative association between gestational weight gain and 
erythropoietin concentration, figure 10. Women with low gestational weight gain were 
mostly women with obesity, who are also recommended to gain less weight during 
pregnancy. Recommendations of optimal gestational weight gain differs with pre-gestational 
BMI and are 5-9 kg and 11.5-16 kg for obese and normal weight women, respectively. 
Women with low gestational weight gain, under the recommendation for BMI category, had 
higher mean erythropoietin concentrations than women with recommended gestational 
weight gain and higher than women with high gestational weight gain, both among obese and 
normal weight women.  
In study IV we try to find placental explanations for the increased risk of term stillbirth with 
increasing BMI. However, the number of placental findings among healthy pregnancies are 
also obvious. It is true that placental hypoplasia and delayed villous maturation are more 
common in pregnancies complicated by term stillbirth, however also present in one third to 
one fourth of the uncomplicated controls. A long cord, velamentous or marginal cord 
insertion and hyper coiled umbilical cord were associated with stillbirth, although hypo coiled 
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cord was much more common and did not have a positive association with stillbirth. 
Placental infarctions and placental thrombosis are common both in placentas with live-born 
and stillborn infants in this sample, not significantly associated with stillbirth, table 3. 
However, there will be cases with massive infarctions or massive placental thrombosis 
possibly causative of stillbirth. Umbilical cord thrombosis was associated with stillbirth 
among obese women, however not among normal weight women.  
Table 3: Placental variables comparing placentas from term live born and stillborn infants 
Fetal weight and placental 
characteristics Live born N=222 Stillborn N=358 P-value 
Fetal weight, g 3480 (3240,3830) 3220 (2877.5,3567.5) <0.001 
SGA <10th percentile 15 (6.76%) 88 (24.79%) <0.001 
Placental weight, g 495 (429.25,569.5) 429 (365.75,498.5) <0.001 
Fetal weight/Placental weight 7.26 (6.6,7.81) 7.56 (6.65,8.62) 0.002 
Placental hypoplasia (n, %) 61 (27.48%) 186 (51.96%) <0.001 
Placental hyperplasia (n, %) 29 (13.06%) 18 (5.03%) 0.001 
Abnormal shape of placenta (n, %) 27 (12.16%) 58 (16.62%) 0.181 
Cord long for gw (n, %) 26 (11.71%) 117 (35.03%) <0.001 
Margin cord incision (n, %) 14 (6.31%) 54 (15.34%) 0.002 
High coiling index (n, %) 4 (1.8%) 31 (8.96%) 0.001 
Low coiling index (n, %) 61 (27.48%) 51 (14.74%) <0.001 
Umbilical cord knot (n, %) 4 (1.82%) 27 (7.74%) 0.005 
Deficient villous maturation (n, %) 60 (27.03%) 139 (39.49%) 0.003 
Placental Infarction (n, %) 43 (19.37%) 91 (25.42%) 0.114 
Intervillous Thrombosis (n, %) 84 (37.84%) 121 (34.47%) 0.466 
Thrombosis Placenta (n, %) 57 (25.68%) 19 (29.23%) 0.681 
Thrombosis Umbilical cord (n, %) 19 (8.6%) 44 (12.54%) 0.184 
Chorioamnionitis (n, %) 56 (25.23%) 149 (42.45%) <0.001 
Vasculitis (n, %) 31 (14.03%) 58 (16.52%) 0.494 
Funisitis (n, %) 5 (2.25%) 23 (6.55%) 0.033 
Villitis (n, %) 21 (9.5%) 85 (24.29%) <0.001 
Increased fetal red blood cell count (n, %) 11 (5%) 37 (10.54%) 0.03 
Placental abruptio (n, %) 4 (1.8%) 32 (9.12%) <0.001 
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8 DISCUSSION 
8.1 STUDY I 
The main result of study I was a reasonably good predictive model for risk of LGA infants 
among obese multiparous women, pre-pregnancy or in early pregnancy. The predictor 
contributing most to the predictive capacity was previous child’s birthweight. The predictive 
model of LGA infants among obese primiparous women in early pregnancy was weak.  
The interpretation of a predictive model cannot be based on the AUC only. The incidence or 
prevalence of the outcome as well as consequences of false negative and false positive results 
must be considered. The incidence of LGA infants is high. LGA infants and their mothers, 
are at increased risk during delivery and during life of the LGA infant. However, there is no 
easy solution to decrease the risk of being born LGA. Predictive models may be used to 
choose which women would benefit from an ultrasound with estimation of fetal weight in 
gestational week 36-37. However, our predictive models were not meant to be guiding 
obstetricians in the decisions about mode of delivery or time of delivery. They were meant to 
predict which women would benefit from interventions during pregnancy to decrease the risk 
of the infant to become LGA in the first place. However, no such interventions during 
pregnancy have been able to show a decreased incidence of LGA or affect maternal or 
neonatal outcome except a slightly decreased gestational weight gain and a slight decrease in 
birth weight 55, 170. The decreased concentrations of PAPP-A in early pregnancy among obese 
women, compared to normal weight women, indicate that obesity will affect the pregnancy 
already from conception. To be able to decrease risks of both mother and infant, interventions 
before pregnancy are needed 25, 171. The pre-pregnancy predictive model for obese parous 
women was equally good as the predictive model in early pregnancy. Already after the first 
pregnancy, it is possible to perform a good prediction for risk of LGA for the next pregnancy. 
The predictive capacity is even better if the prediction is made over all BMI categories, figure 
11. Additionally, weight loss between pregnancies decreases the risk of an LGA infant in 
next pregnancy. This is the window of prevention. 
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Figure 11: Prediction for risk of LGA for all women who have given birth before.   
In our sample LGA infants (birthweight > 97th percentile or >2SD) and macrosomic infants 
(birthweight >4 500 g) were almost equally many but to a large part different individuals. The 
most important “predictor” of the macrosomic infants was gestational age, which is 
impossible to use as a predictor since it is not known when the prediction should be made. 
However, the macrosomic infants will, to a large extent be born following a prolonged 
pregnancy as opposed to an LGA infant.        
8.2 STUDY II 
The main result of study II was a predictive model of stillbirth among overweight or obese 
women. The predictive capacity was medium good. However, if SGA (≤10th percentile) was 
introduced in the predictive model the predictive capacity increased to a good capacity, 
indicating a better predictive capacity with estimated fetal weight in the model. SGA infants 
are at increased risk of stillbirth and other adverse outcomes. Fetuses small for gestational age 
are at increased risk even with a broader definition of SGA than the one used in Sweden 122. 
Infants with birthweight between the 5th-10th percentile are at increased risk of mortality and 
asphyxia related injuries even if the risks are more prominent among infants with a 
birthweight < 3rd percentile, which is the definition used in Sweden 8. Obese women have a 
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decreased risk of SGA infants, however SGA infants to obese women are at increased risk of 
mortality and asphyxia related injuries compared to SGA infants to normal weight women 82.   
There was not a significant association between a slower fetal growth between gestational 
weeks 10 and 20 and stillbirth. However, the highest predictive capacity in the cross-
validation was when fetal growth between gestational weeks 10-20 was included in the 
model. Thus, indicating a stronger model if differences in early fetal growth were included in 
the model.    
The incidence of stillbirth is low which will result in a low positive predictive value (the 
proportion of women with a positive test who will suffer from a stillbirth). For women with 
increased risk of adverse outcome the degree of surveillance could be increased. Whatever 
surveillance method used it has to be performed for a large number of women of whom the 
vast majority will never suffer from stillbirth.   
8.3 STUDY III 
The main result in study III was the positive association between BMI and concentration of 
erythropoietin in cord blood.  
When analysis was stratified on mode of delivery there was still a positive significant 
association between BMI and erythropoietin among infants born vaginally. The findings 
indicate that fetuses to obese women have an increased risk of chronic hypoxia before 
delivery, which may make them more vulnerable during delivery and at the end of pregnancy. 
Our knowledge about risk factors and specific findings during pregnancy and delivery will 
affect our decisions about time of delivery, mode of delivery and surveillance during 
pregnancy and delivery, hopefully decreasing risks of infants and women.      
The hypothesis of study III was that the metabolic situation in obese women, with for 
example increased blood glucose levels, and in addition, their larger body mass, with 
increased oxygen demand, would lead to less oxygen transported to the placenta and to the 
fetus. There were no differences in placental lesions associated with fetal hypoxia comparing 
obese and normal weight women. Results were somewhat conflicting, with a positive 
association between obesity and erythropoietin however no differences in placental lesions 
associated with fetal hypoxia comparing obese and normal weight women. If that depends on 
small differences between normal weight women and obese women with uneventful 
pregnancies, if placental analyses are to blunt or if differences in individual pregnancy 
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adaptation and differences in placental response to hypoxia make the placental picture more 
diverged, is an open question.  
8.4 STUDY IV 
The main result of study IV was that umbilical cord abnormalities may explain one third of 
the effect of obesity on risk of stillbirth. Chorioamnionitis could explain approximately 10-15 
% of the effect of obesity on risk of stillbirth.  
Mechanisms behind the association between obesity and stillbirth is multifactorial 67. 
Increased incidence of umbilical cord abnormalities and chorioamnionitis are two possible 
explanations. Our findings indicate that more focus on umbilical cord abnormalities could be 
valuable. To be able to take umbilical cord abnormalities into account in decisions about 
surveillance of the pregnancy or time of delivery, more precise methods of measurement of 
umbilical cord abnormalities are needed. With a reliable method to find umbilical cord knots, 
measure umbilical cord length and coiling index in utero, such findings could be included, 
among other risk factors considered, when deciding about time of delivery or labor and 
pregnancy surveillance.    
Obese women have an increased degree of inflammation perhaps affecting the increased 
findings of chorioamnionitis. To be able to use the knowledge about chorioamnionitis as a 
part of the explanation of the association between obesity and stillbirth a reliable marker of 
chorioamnionitis during pregnancy would be needed. The finding of chorioamnionitis as 
explanation is previously shown and, in that study, it was also shown that c-reactive protein 
was not a good marker for chorioamnionitis 78.    
8.5 OBESITY 
Obesity is a modifiable risk factor with several pregnancy related complications 3, 26. First 
trimester PAPP-A concentrations are lower in obese women as compared to normal weight 
women. Obesity increases the risk of velamentous cord insertion, congenital heart disease and 
miscarriage 7, 172, 173. Hence, obesity will affect the pregnancy as early as already from 
conception. Obesity is still a modifiable risk factor. However, weight loss before pregnancy is 
the method needed to modify risks. During pregnancy, a limited gestational weight gain can 
lead to decreased additional risks. Increased surveillance can potentially find additional risks 
apart from BMI, for example an SGA fetus, GDM or velamentous cord insertion. An 
individual evaluation of each pregnant woman is important. Which are her risk factors? 
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Which are the risk factors of her fetus? A fetus with an estimated weight 10 % below the 
expected weight may be an additional risk of one fetus but not of another.  
Knowledge about risk factors, methods to evaluate risk factors, a thorough individual 
evaluation of each woman’s risks combined, and reasonable decisions based on this 
knowledge, may be a recommendation to decrease stillbirth incidence among obese women.   
8.6 FUTURE RESEARCH 
The incidence of stillbirth has been stable for decades. It is a challenge to make the incidence 
continue to decrease. To be able to do that more knowledge about certain risk groups, causal 
pathways and mechanisms behind stillbirths is needed.  
Ideas of future research projects: 
To investigate placental characteristics in preterm stillbirths stratified on obesity compared to 
live born preterm babies.  
To investigate how risk factors for stillbirth have changed during the two past decades in the 
Stockholm region.  
To investigate the risk of stillbirth among women born in different parts of the world and if 
there are specific risk factors for women with different origin.  
9 ETHICAL CONCIDERATIONS 
9.1 INTEGRITY AND AUTONOMY 
Study I and study II are register based studies. Data are de-identified, so that information 
about a unique woman and her infant is not possible to reach. The participating women 
haven’t given their informed consent to their contribution, which is common in register-based 
studies. These two studies will not affect the women or their infants as long as the 
information about women and infants are de-identified. 
Study III and study IV include comparison between placental lesions from pregnancies 
complicated by obesity compared to placentas from pregnancies with normal weight women. 
These studies include collection of placentas and cord blood samples. The participating 
women were given both oral and written information about the studies. They were given easy 
understandable information and had the possibility to ask questions. After the information, 
the woman decided whether she would like to participate or not. A decision which did not 
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affect the care for her or her infant. The participating women signed a written informed 
consent. All information about the woman and her infant were de-identified as soon as 
possible.   
9.2 RISK-BENEFIT  
For study I and study II the risks for the participants are negligible as long as the information 
about them are de-identified and data handled in a safe way. Good predictive models for both 
LGA and stillbirth is a prerequisite for preventive action.   
In study III and study IV, placentas and cord blood were collected. Most women are not 
interested in the placenta after the delivery. When we were not collecting the placentas, they 
would normally be wasted. Right after the infant is born routine blood samples are taken from 
the cord. The infant can’t feel the stitch in the cord. The blood we will analyze would have 
been wasted if not used in the study.  
Study III and study IV aim to gain more knowledge about the mechanisms to explain the 
well-known association between BMI and stillbirth. We were not allowed to ask about the 
women’s participation before the labor started since it could potentially cause unnecessary 
anxiety because of the increased risk of stillbirth. The women from whom we collected 
placentas and cord blood were healthy controls, a fact which could potentially reduce anxiety. 
Stillbirth is a severe complication which we would like to prevent in all possible cases. The 
number of obese pregnant women are increasing. Thus, it is important to learn more about the 
mechanisms causing the association between BMI and stillbirth in order to be able to take 
preventive action against stillbirth.  
In conclusion; the first two studies carry very small risks. The study design makes it possible 
to give response to the aim of the studies. Study III and study IV have very small risks for the 
mother and infant, and we analyzed placentas and blood samples that would have been 
wasted in normal cases. Deeper knowledge about the mechanisms leading to stillbirth in 
obese women is important. These studies will add a piece of new knowledge to the puzzle 
about the link between stillbirth and obesity.  
9.3 THE POLICY OF EQUALITY  
All women and their infants have been treated equally independent of whether they 
participate in the studies or not. If someone withdrew their participation in the studies, it did 
not affect the treatment of woman or infant.  
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10 SVENSK POPULÄRVETENSKAPLIG 
SAMMANFATTNING 
Kvinnor med högt BMI löper en ökad risk för komplikationer i samband med graviditet och 
förlossning. En av de vanligaste komplikationerna är att föda ett stort barn och en av de 
allvarligaste komplikationerna är att fostret dör i livmodern. Det finns många studier som 
visar på ökade risker för kvinnor med förhöjt BMI, men det finns få studier som belyser 
möjliga orsaker till att riskerna ökar. För att en ska kunna minska riskerna för kvinnor med 
högt BMI under graviditet och förlossning så behöver en ha större kunskap om varför deras 
risker ökar. Vilka är de bakomliggande mekanismerna? Vad skulle behöva åtgärdas för att 
minska riskerna? Vi skulle också behöva veta om det går att säga vilka av dessa kvinnor som 
löper störst risk att drabbas av oönskade utfall. 
Avhandlingen innefattar fyra studier som syftar till att finna de grupper av kvinnor som löper 
högst risk att drabbas av att få ett dödfött barn eller ett barn som är stort för graviditetsveckan, 
samt att finna kopplingar som kan ligga bakom den ökade risken att föda ett dödfött barn som 
ett högt BMI innebär. 
De två första studierna avser att tidigt i graviditeten kunna prediktera dödfödda barn 
respektive barn som föds stora för tiden hos kvinnor med BMI ≥30 respektive BMI ≥ 25. 
Dessa studier baseras på en screeningdatabas från tidig graviditet som sammanlänkats med 
medicinska födelseregistret samt ett register från statistiska centralbyrån. Utifrån data i dessa 
register har prediktiva modeller byggts upp baserade på blodprover tagna tidigt i graviditeten 
(PAPP-A och B-hcg), moderns ålder, BMI, rökvanor, utbildningsnivå, inkomstnivå och 
födelseland. De prediktiva modellerna visar att man med god precision kan prediktera stora 
barn hos kvinnor som tidigare fött barn och att förra barnets födelsevikt är den bästa 
prediktorn. För förstföderskor var den prediktiva kapaciteten svag. Prediktionen för risk att 
föda ett dödfött barn var medelgod. Den gick dock att förbättra genom att en låg födelsevikt 
lades till i modellen vilket indikerar att modellen skulle fungera bättre om en la till uppskattad 
fostervikt. 
Den tredje studien utreder risken att fostret ska drabbas av kronisk syrebrist i livmodern 
kopplat till mammans BMI som i sin tur skulle kunna öka risken för fostrets död före 
förlossningen. Den fjärde studien försöker hitta bidragande orsaker till den ökade risk för 
fosterdöd som finns hos kvinnor med BMI ≥ 30. I den tredje studien har analyser av 
moderkakor jämförts mellan kvinnor med BMI 18.5-24.9 och kvinnor med BMI ≥ 30. 
Koncentrationen av erythropoietin, ett protein som ökar vid syrebrist, i navelsträngsblod har 
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också jämförts mellan dessa grupper. Generellt är erytropoetinkoncentrationen lite högre hos 
barn till kvinnor med BMI ≥ 30, vilket talar för en ökad förekomst av en låggradig långvarig 
syrebrist. Det var inga tydliga skillnader i analysen av moderkakorna. I den fjärde studien 
jämförs analyser av moderkakor mellan normalviktiga kvinnor med levande födda barn och 
dödfödda barn och kvinnor med BMI ≥ 30 med levande födda barn och dödfödda barn med 
syfte att förklara skillnaden i risk. Resultaten visar att långa navelsträngar som är fästa långt 
ut i moderkakan och snurrade många varv kan förklara ungefär en tredjedel av riskökningen 
hos kvinnor med BMI ≥ 30. Akut inflammation i moderkakan kan förklara ca 10-15 % 
ytterligare av riskökningen hos kvinnor med BMI ≥ 30. 
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